{"@context":"https://schema.org","@type":"DietarySupplement","id":"https://nutripedia.co.uk/items/omega-3-fish-oil","url":"https://nutripedia.co.uk/items/omega-3-fish-oil","name":"Omega-3 Fish Oil","category":"Wellness","tagline":"Anti-inflammatory essential fats for heart, brain, and joint health.","verdict":"strong","evidenceRating":4,"verdictSummary":"Strong evidence for cardiovascular benefit (EPA/DHA combined >2 g/day), anti-inflammatory effects, and triglyceride reduction. Mixed evidence for cognitive enhancement in healthy adults.","dosage":{"recommended":"1–3","unit":"g combined EPA+DHA","timing":"With food","notes":"Look for products with high EPA+DHA concentration. Triglyceride form absorbs better than ethyl ester."},"keyBenefits":["Reduces systemic inflammation","Supports cardiovascular health and triglyceride reduction","Important for brain structure and function","May improve joint comfort and mobility"],"warnings":["Fish burps at high doses — enteric-coated capsules help","May increase bleeding time — caution with blood thinners","Quality varies widely — look for third-party purity testing"],"evidenceSummary":null,"dosing":null,"safety":null,"whoMightBenefit":[],"whoShouldAvoid":[],"regulatoryNotes":null,"faqs":[{"question":"What does the research say about omega-3 fish oil and heart health?","answer":"Evidence is dose- and context-dependent. The REDUCE-IT trial (n=8,179, PMID: 30415628) found that prescription-dose icosapentaenoic acid (4 g/day) reduced major cardiovascular events by 25% over 4.9 years in a high-risk population. However, the VITAL trial (n=25,871, PMID: 30415630) found that 1 g/day of conventional fish oil did not significantly reduce the primary CVD composite endpoint, though secondary analyses showed a significant reduction in myocardial infarction. Meta-analyses of standard fish oil supplements show consistent triglyceride reduction but inconsistent benefit for hard cardiovascular outcomes."},{"question":"What dosage ranges have been studied for omega-3 fish oil?","answer":"Trials have used a wide range. For triglyceride reduction, effective doses start at approximately 2 g/day combined EPA+DHA. The REDUCE-IT trial used 4 g/day pure EPA (icosapentaenoic acid). Most intervention trials for general cardiovascular and anti-inflammatory effects use 1–3 g/day combined EPA+DHA. For rheumatoid arthritis, benefit has been observed at ≥2.7 g/day EPA+DHA from 12 weeks. Product labels can be misleading — 1,000 mg fish oil capsules often contain only 300–500 mg combined EPA+DHA; checking the supplement facts panel for the EPA+DHA content is essential."},{"question":"What side effects have been reported in trials of omega-3 fish oil?","answer":"Gastrointestinal side effects — including fish burps (eructation), nausea, and loose stools — are the most commonly reported adverse events at doses above 3 g/day. Enteric-coated formulations reduce fishy aftertaste in comparative studies. At pharmacological doses (≥3 g/day), fish oil has a measurable antiplatelet effect, extending bleeding time; the European Food Safety Authority notes that doses up to 5 g/day are safe for the general population. Rare cases of atrial fibrillation were reported in the ASCEND and VITAL-Rhythm substudies at high doses."},{"question":"Is there evidence for omega-3 supplementation during pregnancy?","answer":"DHA is a structural component of fetal brain and retinal development. Observational studies consistently associate higher maternal DHA status with improved neurodevelopmental outcomes. The CHILD study and several RCTs have investigated EPA+DHA supplementation in pregnancy; NICE recommends pregnant women eat 1–2 portions of oily fish per week as the preferred route to EPA+DHA. Trials report that supplementation with 200–1,000 mg DHA/day during pregnancy is well-tolerated; the European Commission has established an AI of 200 mg/day DHA during pregnancy and lactation."},{"question":"What forms of omega-3 have the strongest evidence base?","answer":"Triglyceride (TG) form omega-3s demonstrate 25–73% higher bioavailability than ethyl ester (EE) form in pharmacokinetic studies, particularly when taken with a high-fat meal. Re-esterified triglyceride (rTG) form closely matches the natural oil found in fish. Most consumer products are ethyl esters. Krill oil contains omega-3s in phospholipid form, which some studies suggest improves brain uptake, though head-to-head clinical trial evidence versus fish oil TG form is limited. Algal oil (EPA+DHA from microalgae) is the evidence-based alternative for those avoiding fish."},{"question":"What do NHS and EFSA say about omega-3 fish oil?","answer":"The NHS recommends at least two portions of fish per week, one of which should be oily fish, as the preferred dietary route to EPA+DHA. The NHS advises those who do not eat fish can take omega-3 supplements. EFSA has authorised health claims for EPA and DHA combined: maintenance of normal blood triglyceride levels (at 2 g/day), normal blood pressure (at 3 g/day), normal cardiac function (at 250 mg/day), and maintenance of normal brain function and vision (at 250 mg DHA/day)."},{"question":"What does the research say about omega-3 and inflammation?","answer":"Mechanistic and clinical evidence shows that EPA and DHA compete with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, reducing the synthesis of pro-inflammatory eicosanoids (prostaglandin E2, leukotriene B4) and promoting pro-resolving mediators (resolvins, protectins). Meta-analyses show consistent reductions in C-reactive protein, IL-6, and TNF-α with supplementation in populations with elevated baseline inflammation. A Cochrane-level review by Calder (2017, PMID: 28838588) concluded EPA and DHA have anti-inflammatory properties, with effects proportional to baseline inflammatory status."}],"research":{"totalCount":15,"papers":[{"title":"Omega-3 Fatty Acids — Health Professional Fact Sheet","year":2024,"journal":"NIH Office of Dietary Supplements","doi":null,"pmid":"","url":"https://pubmed.ncbi.nlm.nih.gov//","studyDesign":"regulatory","fields":[],"conclusion":"NIH ODS synthesis of evidence concludes omega-3 fatty acids (EPA and DHA) support cardiovascular health and triglyceride reduction at higher doses. Evidence for cognitive and mental health benefits is promising but not conclusive. Supplements are generally safe; common adverse effects are mild GI symptoms.","abstract":"","citationCount":0},{"title":"The Relationship of Omega-3 Fatty Acids with Dementia and Cognitive Decline: Evidence from Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers","year":2023,"journal":"American Journal of Clinical Nutrition","doi":"10.1016/j.ajcnut.2023.04.001","pmid":"37028557","url":"https://doi.org/10.1016/j.ajcnut.2023.04.001","studyDesign":"systematic-review","fields":[],"conclusion":"Systematic review of 48 prospective cohort studies found that higher omega-3 dietary intake and long-term supplementation were associated with approximately 20% reduced risk of cognitive decline or dementia. Each 0.1 g/day increase in DHA or EPA intake was associated with 8–10% lower cognitive decline risk.","abstract":"","citationCount":0},{"title":"Effects of long-chain omega-3 polyunsaturated fatty acids on reducing anxiety and/or depression in adults: A systematic review and meta-analysis of randomised controlled trials","year":2023,"journal":"Prostaglandins, Leukotrienes and Essential Fatty Acids","doi":"10.1016/j.plefa.2023.102572","pmid":"37028202","url":"https://doi.org/10.1016/j.plefa.2023.102572","studyDesign":"meta-analysis","fields":[],"conclusion":"Systematic review of RCTs confirmed EPA-enriched omega-3 formulations (≥60% EPA, 1–2 g/day) significantly reduced depression severity in adults. Higher EPA doses (≥2 g/day) did not confer additional benefit. Evidence for anxiety reduction was present but limited by heterogeneity across trials.","abstract":"","citationCount":0},{"title":"Efficacy of the omega-3 fatty acids supplementation on inflammatory biomarkers: An umbrella meta-analysis","year":2022,"journal":"International Immunopharmacology","doi":"10.1016/j.intimp.2022.109104","pmid":"35914448","url":"https://doi.org/10.1016/j.intimp.2022.109104","studyDesign":"meta-analysis","fields":[],"conclusion":"Umbrella meta-analysis of 32 prior meta-analyses confirmed that n-3 PUFA supplementation significantly reduces serum CRP, TNF-α, and IL-6 concentrations across a broad range of adult health conditions, supporting omega-3 as an adjuvant anti-inflammatory intervention.","abstract":"","citationCount":0},{"title":"Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis","year":2021,"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.121.055654","pmid":"34612056","url":"https://doi.org/10.1161/CIRCULATIONAHA.121.055654","studyDesign":"meta-analysis","fields":[],"conclusion":"Across 7 RCTs (81,210 participants), marine omega-3 supplementation was associated with a statistically significant increased risk of atrial fibrillation. Risk was dose-dependent, with approximately 10–11% higher relative risk per additional 1 g/day, raising safety concerns at higher supplemental doses.","abstract":"","citationCount":0},{"title":"Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis","year":2021,"journal":"eClinicalMedicine (The Lancet)","doi":"10.1016/j.eclinm.2021.100997","pmid":"34505026","url":"https://doi.org/10.1016/j.eclinm.2021.100997","studyDesign":"meta-analysis","fields":[],"conclusion":"Meta-analysis of 38 RCTs found omega-3 fatty acids reduced cardiovascular mortality and major adverse events. EPA monotherapy demonstrated significantly greater reductions in cardiovascular outcomes than combined EPA+DHA formulations, suggesting formulation composition substantially influences efficacy.","abstract":"","citationCount":0},{"title":"Fish oil supplements, oxidative status, and compliance behaviour: Regulatory challenges and opportunities","year":2021,"journal":"PLOS ONE","doi":"10.1371/journal.pone.0244688","pmid":"33382790","url":"https://doi.org/10.1371/journal.pone.0244688","studyDesign":"case-study","fields":[],"conclusion":"Analysis of 44 commercially available fish oil supplements found a substantial proportion exceeding GOED voluntary oxidation limits for peroxide value, anisidine value, or TOTOX, highlighting that product quality is inconsistent at retail and underscoring the need for third-party certification such as IFOS.","abstract":"","citationCount":0},{"title":"Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial","year":2020,"journal":"JAMA","doi":"10.1001/jama.2020.22258","pmid":"33190147","url":"https://doi.org/10.1001/jama.2020.22258","studyDesign":"rct","fields":[],"conclusion":"The STRENGTH trial found that high-dose EPA+DHA omega-3 carboxylic acid (4 g/day) did not reduce major adverse cardiovascular events versus corn oil placebo in 13,078 statin-treated high-risk patients. The trial was terminated early for futility, with a nearly 70% increase in atrial fibrillation risk observed in the omega-3 group.","abstract":"","citationCount":0},{"title":"Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants","year":2019,"journal":"Journal of the American Heart Association","doi":"10.1161/JAHA.119.013543","pmid":"31567003","url":"https://doi.org/10.1161/JAHA.119.013543","studyDesign":"meta-analysis","fields":[],"conclusion":"Pooled analysis of 13 RCTs (127,477 participants) found marine omega-3 supplementation significantly reduced myocardial infarction, coronary heart disease death, total CVD events, and CVD mortality. Higher doses were associated with greater cardiovascular risk reduction, supporting a dose-dependent benefit.","abstract":"","citationCount":0},{"title":"Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association","year":2019,"journal":"Circulation","doi":"10.1161/CIR.0000000000000709","pmid":"31422671","url":"https://doi.org/10.1161/CIR.0000000000000709","studyDesign":"systematic-review","fields":[],"conclusion":"The AHA advisory concludes that prescription omega-3 fatty acids (EPA+DHA or EPA-only) at 4 g/day are an effective and safe option for reducing triglycerides by 20–30% as monotherapy or adjunct to other lipid-lowering agents in adults with severe hypertriglyceridemia (≥500 mg/dL).","abstract":"","citationCount":0},{"title":"Efficacy of omega-3 PUFAs in depression: A meta-analysis","year":2019,"journal":"Translational Psychiatry","doi":"10.1038/s41398-019-0515-5","pmid":"31383846","url":"https://doi.org/10.1038/s41398-019-0515-5","studyDesign":"meta-analysis","fields":[],"conclusion":"Meta-analysis of 26 RCTs (2,160 participants) found a significant overall benefit of omega-3 PUFAs on depression symptoms (SMD −0.28). Formulations with ≥60% EPA at ≤1 g/day showed the clearest antidepressant effect; DHA-dominant formulations did not demonstrate significant benefit.","abstract":"","citationCount":0},{"title":"Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer","year":2019,"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa1811403","pmid":"30415637","url":"https://doi.org/10.1056/NEJMoa1811403","studyDesign":"rct","fields":[],"conclusion":"Among 25,871 US adults in the VITAL trial, 1 g/day omega-3 supplementation (840 mg EPA+DHA) did not significantly reduce major cardiovascular events or cancer incidence versus placebo over 5.3 years, though myocardial infarction risk was reduced by 28%, with greatest benefit in those with low baseline fish intake.","abstract":"","citationCount":0},{"title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","year":2019,"journal":"New England Journal of Medicine","doi":"10.1056/NEJMoa1812792","pmid":"30415628","url":"https://doi.org/10.1056/NEJMoa1812792","studyDesign":"rct","fields":[],"conclusion":"In the REDUCE-IT trial, 4 g/day of highly purified EPA ethyl ester (icosapent ethyl) reduced major ischemic cardiovascular events by 25% relative to placebo (mineral oil) among 8,179 statin-treated patients with elevated triglycerides, though the mineral oil placebo may have inflated the apparent benefit.","abstract":"","citationCount":0},{"title":"Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety","year":2015,"journal":"Journal of Nutritional Science","doi":"10.1017/jns.2015.21","pmid":"26688721","url":"https://doi.org/10.1017/jns.2015.21","studyDesign":"case-study","fields":[],"conclusion":"Testing of North American retail omega-3 supplements found that approximately 50% exceeded voluntary oxidation safety benchmarks (TOTOX, peroxide value, anisidine value), with liquid formulations and children's products showing the highest non-compliance rates. Unflavoured capsules demonstrated superior oxidative stability.","abstract":"","citationCount":0},{"title":"Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA)","year":2012,"journal":"EFSA Journal","doi":"10.2903/j.efsa.2012.2815","pmid":"","url":"https://doi.org/10.2903/j.efsa.2012.2815","studyDesign":"regulatory","fields":[],"conclusion":"EFSA concluded that insufficient data exist to establish a formal Tolerable Upper Intake Level for EPA, DHA, or DPA. However, combined supplemental EPA+DHA up to 5 g/day, EPA alone up to 1.8 g/day, and DHA alone up to 1 g/day do not raise safety concerns in healthy adults.","abstract":"","citationCount":0}]},"machineReadable":{"markdownUrl":"https://nutripedia.co.uk/items/omega-3-fish-oil/markdown","jsonUrl":"https://nutripedia.co.uk/items/omega-3-fish-oil/json","llmsTxt":"https://nutripedia.co.uk/llms.txt"},"disclaimer":"Informational supplement research only. Not medical advice. Consult a qualified healthcare professional before taking supplements.","lastReviewed":"2026-04-20T00:00:00.000Z","updatedAt":"2026-04-20T00:00:00.000Z"}